Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1CNS 1

Conditions

Brain Neoplasms 14Glioblastoma 6Neoplasms 4Lymphoma, Non-Hodgkin 4Breast Neoplasms 4Testicular Neoplasms 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Neuroblastoma 3Neoplasm Metastasis 3Meningeal Carcinomatosis 3Lymphoma 3Glioma 3Burkitt Lymphoma 3Vomiting 2Testicular Germ Cell Tumor 2Sezary Syndrome 2Recurrence 2Radiation Injuries 2Primary Myelofibrosis 2Pdgfra-Associated Chronic Eosinophilic Leukemia 2Oligodendroglioma 2Nausea 2Myeloproliferative Disorders 2Mycosis Fungoides 2Multiple Myeloma 2Melanoma 2Medulloblastoma 2Lymphoma, T-Cell, Cutaneous 2Lymphoma, Mantle-Cell 2Lymphoma, Large-Cell, Immunoblastic 2

Interventions

cabozantinib 3selpercatinib 2vandetanib 1tumor necrosis factor-alpha, CNGRC fusion protein, human 1tipifarnib 1temsirolimus 1sargramostim 1rovalpituzumab tesirine 1pentetreotide 1lutetium Lu 177 dotatate 1lenvatinib 1cixutumumab 1aldesleukin 1Vinorelbine 1Trastuzumab 1Tamoxifen 1Sirolimus 1Semaxinib 1Salts 1Restraint, Physical 1Radiotherapy 1Paclitaxel 1Octreotide 1Magnetic Resonance Spectroscopy 1Gefitinib 1Fluorodeoxyglucose F18 1FAPI-46 1Everolimus 1Doxorubicin 1Docetaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma, Medullary × Dexamethasone × CNS × Clear all
NCT02709889 2020-10-19

Rovalpituzumab Tesirine in Delta-Like Protein 3-Expressing Advanced Solid Tumors

AbbVie

Phase 1/2 Terminated
200 enrolled 21 charts
CNSDermatologic

Glioblastoma, Melanoma, Carcinoma, Medullary

Data powered by HemOnc (CC BY 4.0) Colophon âš¡